tradingkey.logo

Aclarion Inc

ACON
2.750USD
+0.390+16.53%
Close 02/06, 16:00ETQuotes delayed by 15 min
1.60MMarket Cap
LossP/E TTM

Aclarion Inc

2.750
+0.390+16.53%

More Details of Aclarion Inc Company

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Aclarion Inc Info

Ticker SymbolACON
Company nameAclarion Inc
IPO dateApr 22, 2022
CEONess (Brent)
Number of employees6
Security typeOrdinary Share
Fiscal year-endApr 22
Address8181 Arista Place
CityBROOMFIELD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80021
Phone18332752266
Websitehttps://aclarion.com/
Ticker SymbolACON
IPO dateApr 22, 2022
CEONess (Brent)

Company Executives of Aclarion Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.00
+10.00%
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
+1.00%
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
--
--
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.00
+10.00%
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
+1.00%
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
CAPTRUST Financial Advisors
1.49%
DRW Securities, LLC
0.41%
The Vanguard Group, Inc.
0.24%
Tower Research Capital LLC
0.09%
Geode Capital Management, L.L.C.
0.07%
Other
97.71%
Shareholders
Shareholders
Proportion
CAPTRUST Financial Advisors
1.49%
DRW Securities, LLC
0.41%
The Vanguard Group, Inc.
0.24%
Tower Research Capital LLC
0.09%
Geode Capital Management, L.L.C.
0.07%
Other
97.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.17%
Hedge Fund
0.09%
Investment Advisor/Hedge Fund
0.07%
Other
97.67%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
15
31.25K
1.59%
--
2025Q3
15
31.25K
0.88%
+26.14K
2025Q2
9
2.11K
0.08%
+1.65K
2025Q1
16
366.00
0.00%
+366.00
2024Q4
14
--
0.00%
--
2024Q3
14
--
0.00%
--
2024Q2
21
--
0.00%
--
2024Q1
22
--
0.00%
--
2023Q4
21
--
0.00%
--
2023Q3
20
--
0.00%
--
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
CAPTRUST Financial Advisors
10.00K
1.49%
+10.00K
--
Sep 30, 2025
DRW Securities, LLC
11.57K
1.72%
+11.57K
--
Sep 30, 2025
The Vanguard Group, Inc.
6.78K
1.01%
--
--
Nov 30, 2025
Tower Research Capital LLC
581.00
0.09%
+506.00
+674.67%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.06K
0.31%
--
--
Nov 30, 2025
UBS Financial Services, Inc.
--
0%
-1.73K
-100.00%
Sep 30, 2025
BNP Paribas Securities Corp. North America
230.00
0.03%
+230.00
--
Sep 30, 2025
Ness (Brent)
13.00
0%
+10.00
+333.33%
Nov 26, 2025
Thramann (Jeffrey John)
10.00
0%
+10.00
--
May 09, 2025
Neal (David K)
2.00
0%
+2.00
--
May 09, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Date
Ex-dividend Date
Type
Ratio
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 02, 2024
Merger
16→1
Jan 02, 2024
Merger
16→1
View more
KeyAI